This commentary discusses nephron protection in diabetic kidney disease and describes the way in which renin–angiotensin system inhibitors and the sodium–glucose cotransporter 2 inhibitor empagliflozin have renoprotective effects.
No takes yet. Share an insight, caveat, or question.
Anders et al. (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: